Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial - PubMed
5 hours ago
- #clinical trial
- #antibody-drug conjugate
- #triple-negative breast cancer
- Datopotamab deruxtecan (Dato-DXd) was compared to chemotherapy in a phase III trial for untreated advanced triple-negative breast cancer patients ineligible for immunotherapy.
- Dato-DXd significantly improved progression-free survival (median 10.8 vs 5.6 months) and overall survival (median 23.7 vs 18.7 months) over chemotherapy.
- Safety profiles were manageable, with grade ≥3 treatment-related adverse events occurring in 33% (Dato-DXd) vs 29% (chemotherapy) of patients, and no treatment-related deaths reported.